Little is known about the role for JNK mitochondrial signaling in cardiomyocyte cell death. Results: Global and mitochondrial inhibition of JNK protects against I/R injury reducing infarct volume. Conclusions: Blocking JNK mitochondrial translocation or JNK inhibition may be an effective treatment for I/R-induced cardiomyocyte death. Significance: These findings suggest a new molecular target for JNK inhibition. Summary: To build upon recent findings that mitochondrial JNK signaling is inhibited by selectively blocking the interaction between JNK and Sab, we utilized a cell permeable peptide to demonstrate that ischemia reperfusion (I/R) injury could be protected in vivo and that JNK mitochondrial signaling was the mechanism by which reactive oxygen species (ROS) generation, mitochondrial dysfunction, and cardiomyocyte cell death occurred. We also demonstrated that 5mg/kg of a selective JNK inhibitor (SR-3306) was able to protect against I/R injury reducing infarct volume by 34% (p<0.05) while also decreasing I/R-induced increases in activity of creatine phosphokinase (CPK) and creatine kinase-MB (CK-MB). TUNEL staining showed the % TUNEL positive nuclei in rat hearts increased 10-fold after I/R injury, and that this was reduced 4-fold (p <0.01) by SR-3306. These data suggest that blocking JNK mitochondrial translocation or JNK inhibition prevented ROS increases and mitochondrial dysfunction and may be an effective treatment for I/R-induced cardiomyocyte death.
JNK inhibition prevented ROS increases and mitochondrial dysfunction and may be an effective treatment for I/R-induced cardiomyocyte death.
The role of mitochondrial JNK is emerging as a significant new area of study and the resulting oxidative stress, mitochondrial dysfunction and cell death caused by JNK translocation has been associated with numerous cell types, tissues, and disease states (1) (2) (3) (4) (5) (6) . Beginning in 2000, and following with a series of subsequent reports over the next four years Davis, Flavell, and colleagues utilized JNK deficient mouse embryonic fibroblasts (MEFs) to establish that JNK was required for TNF-α-stimulated ROS production and cytochrome c-mediated cell death, and that Bcl2 family members were essential components of this mitochondrial apoptotic machinery (7) (8) (9) (10) .
It has long been established that oxidative stress and ischemia/reperfusion injury causes cardiomyocyte death. Many studies have linked activation of the JNK mitochondrial pathway to cardiomyocyte cell death both in vitro and in vivo (1, (11) (12) (13) . For example, Molkentin and colleagues showed that jnk1-/-or jnk2-/-, or transgenic mice expressing dominant negative JNK1/2 showed less injury and cellular apoptosis following I/R injury in vivo (13) . Gottlieb and colleagues demonstrated activation of JNK in rabbits subjected to coronary artery ligation followed by reperfusion in vivo as well as in vitro in isolated adult rabbit cardiomyocytes. In the latter case, virally expressed dominant negative JNK2 or JNKinteracting protein-1 (JIP) were shown to be protective against simulated I/R in these cells (12) . Finally, Ferrandi et al. showed that inhibition of JNK by AS601245, a JNK small molecule ATP competitive inhibitor, decreased cardiomyocyte apoptosis and infarct size in rats after I/R suggesting a therapeutic benefit for JNK inhibition (11) . Importantly, none of these reports studied the molecular interactions of JNK with the mitochondria, and none measured ROS generation, protein carbonylation, or mitochondrial function in vitro or in vivo.
Given our recent work where we showed that mitochondrial JNK signaling initiates physiological changes in HeLa cells stressed with anisomycin resulting in amplification of ROS (6) , and the ability to selectively block the subsequent mitochondrial dysfunction and cell death associated with translocation(14), we decide to see if these effects could be generated in cardiomyocyte-like H9c2 cells and during I/R in vivo. In 2002 Wiltshire et al. established the mitochondrial membrane protein, Sab (SH3BP5) as the JNK-interacting binding partner for JNK mitochondrial association(15).
Thus, we designed a retro-inverso peptide containing the HIV-Tat sequence along with 20 residues from the Sab KIM1 domain (Tat-Sab KIM1 ) which could be used for in vivo purposes(14). The current study was designed to test if blocking JNK translocation to the mitochondria would prevent oxidative stress-induced cardiomyocyte death in vitro or I/R-induced cardiomyocyte death in vivo. To do this we utilized rat H9c2 cardiomyocyte-like cells and the I/R model in rats and monitored ROS generation, mitochondrial membrane potential (MMP), and cell death in vitro, and protein carbonylation, lipid peroxidation, CPK and CK-MB activity, apoptosis, and infarct volume in vivo. The major findings showed that oxidative and I/Rstress induced JNK translocation to the mitochondria, and blocking this translocation with Tat-Sab KIM1 peptide reduced ROS generation, increased MMP, and reduced cell death in vitro, while decreasing I/R-induced protein carbonylation, and lipid peroxidation levels and decreasing infarct volumes and apoptosis in vivo. Moreover, our results showed that blocking JNK translocation to the mitochondria was similarly as effective at reducing all of the in vitro endpoints as well as reducing infarct volumes as was inhibiting the catalytic activity of JNK. These results suggest that inhibition of JNK mitochondrial signaling may be a new mechanism and molecular target for treating I/R injury.
Experimental Procedures

Materials:
Tat-Scramble (LPSVFGDVGAPSRLPEVSLSPPRRRQRRKK RG-NH 2 ) and Tat-Sab KIM1 (GFESLSVPSPLDLSGPRVVAPPRRRQRRKK RG-NH 2 ) peptides were purchased from Neo Peptide.
Cell Culture: H9c2 cells and primary human cardiomyocytes (ATCC) were grown at normal cell culture conditions (37 o C and 5% CO 2 ) in DMEM (Invitrogen) supplemented with 10% fetal bovine serum and penicillin/streptomycin. To assure that the cells were actively growing, only cells at ~80% confluency and between passages five and fifteen were used in our experiments. H9c2 cells and primary human cardiomyocytes were exposed to 500nM SR-3306, 500 nM SR-3562, 0.01% DMSO vehicle control, 10µM Tat-Sab KIM1 and 10µM TatScramble 30 minutes prior to the addition of stress.
To induce oxidative stress and mitochondrial dysfunction in H9c2 cells and primary human cardiomyocytes, we added 100 µM hydrogen peroxide (H 2 O 2 )/FeSO 4 or 100 µM hydrogen peroxide (H 2 O 2 )/FeSO 4 directly to the media of the cells. The cells were exposed to H 2 O 2 /FeSO 4 for the times indicated in the experiments.
Mitochondria Isolation: Mitochondria were isolated similarly to the method described by Palloti and Lenaz (16) and as we previously described (6, 14) .
Mitochondria Enrichment: Mitochondria were isolated similarly to the method described by Palloti and Lenaz(16) and as we previously described (6, 14 Tris-HCl, pH 6.7), and it was disrupted with an ice-cold Dounce homogenizer (three strokes). The pellet homogenate was centrifuged at 5,000xg for 10 minutes at 4 o C. The pellet was then suspended in lysis buffer for either Western blot analysis or immunopreciptiation. All buffers contained both phosphatase and protease inhibitors to protect signaling components.
Outer Mitochondrial Membrane and Mitoplast Preparation:
The outer mitochondrial membrane preparation was obtained by methods described in Schnaitman et al. (17) .
Nuclear Subcellular Fractionation:
The protocol used is as previously described (6, 14) .
Mitochondrial
Superoxide Generation: Mitochondrial superoxide production was monitored by utilizing the mitochondrial sensitive dye MitoSOX-Red (Invitrogen) (18) 
Membrane Potential: Mitochondrial membrane potential was monitored using the JC-1 dye kit (Cayman Chemical). Cells were seeded in a 96-well black-walled, clear-bottomed plate as described in MitoSOX staining above. The cells were then stained with 5µM JC-1 for 20 minutes as indicated in the manufacturer's protocol. The cells were washed 3 times in HBSS, and covered in pre-warmed HBSS for fluorescence measurements. The green JC-1 species were detected by exciting at 460nm and monitoring emission at 488nm. JC-1 aggregate staining was normalized to JC-1 monomer staining.
Cell Viability: Cell viability of H9c2 cells and primary human cardiomyocytes was monitored by MTT assay (Cayman Chemical). Cells (H9c2 and primary human cardiomyocytes -20,000 cells/well) were seeded in a 96-well plate (clear bottom) and treated as described in the text. At the culmination of each treatment the cells were treated with the MTT reagent. Absorbance was monitored in a SpectraMax e5 plate reader (Molecular Devices).
Biological Replicates and Statistics:
A minimum of four biological replicates were considered for all cell-based studies. For mitochondrial enrichments, a minimum of three biological replicates were used. Biochemical assays, fluorometric detection of superoxide, and other cellular measures were done with a minimum of five experimental replicates. To determine statistical significance a student's paired t-test was employed. Statistical significance is indicated by (*) in figures when the p-value is less than 0.05.
Western Blotting: Western blot analysis was performed as described (6, 14, 19 o C until use. Cover slips were quenched in 100mM glycine for 20 minutes. Cells were permeabilized in PBS supplemented with 0.1% Triton X-100, and then cells were block in PBS with 0.01% Triton X-100 and 5% bovine serum albumin (BSA). Next, cells were incubated with primary antibodies recognizing active JNK (Phospho-JNK, 1:200) and Sab (1:150) for 2.5 hours at room temperature. Cells were then incubated with goat anti-rabbit AlexaFluor 566 and donkey antimouse AlexaFluor 488 secondary antibodies for 1.5 hours at room temperature. After each antibody incubation cells were washed in PBS. Coverslips were mounted using Vectasheild/DAPI on slides. Fluorescence microscopy was conducted using 100X magnification on an Olympus microscope. Exposures for each channel are indicated as follows: DAPI: 0.05ms, FITC, 0.34ms, and TRITC, 0.52ms. The gain was sent at 4.3.
Images were cropped in Microsoft Powerpoint without any prior alteration in a graphics suite.
Myocardial ischemia/reperfusion injury: Adult Sprague Dawley (SD) rats weighing 250-350g were used. A left thoracotomy was made between the fourth and the fifth rib and a 6-0 vicryl suture was passed under the left anterior descending coronary artery (LAD) just below the left atrium. To occlude the artery a snare was formed by threading the suture ends through a hole made in a 0.4 mm piece of polyethylene tubing. The snare was tightened against the artery until blanching of the apex was evident and then secured tightly with a micro clamp. The LAD was occluded for 30 minutes followed by release. The chest cavity was closed and the animal was gradually weaned from the respirator. Sham operated rats served as surgical controls and were subjected to the same surgical procedures as the experimental rats, with the exception that the LAD was not occluded.
To measure phosho-c-jun and phospho-JNK, animals were euthanized after 30 minutes, 1, 2, 6, and 24 hours of reperfusion. Hearts were transcardially perfused with cold PBS (pH 7.4) and myocardial tissue of the left ventricle was quickly collected and frozen in liquid nitrogen.
To measure the efficacy of a JNK inhibitor, SR-3306 (5 mg/kg) was administered as an IV bolus (1.5 mg/kg, ~0.4 ml) 5 minutes before the end of ischemia followed by continuous IV infusion via a Harvard 22 syringe pump (18 µg/kg/min) for 18 hours following reperfusion. The control group received DMSO/Tween 80/H 2 0 (10/10/80) while the positive control group received 3-aminobenzamide (3-AB, 9 mg/ml). Following 18 hours, the rats were euthanized. The heart was removed and five to six biventricular sections of similar thickness were made perpendicular to the long axis of the heart and incubated in 1% triphenyl tetrazolium chloride (TTC) in PBS for 10 minutes at 37°C. Samples were stored in 10% formalin.
SR-3306 Infarct Size Analysis:
To measure the efficacy of a SR-3306, each heart section stained with Evans Blue and TTC was photographed on both sides for each group (SR-3306, vehicle, 3AB; n= 8). The infarct size was delineated and calculated for both sides using Adobe Photoshop CS3 software. Infarct size was expressed as the ratio of infarct area in both the total area of the left ventricle. The cumulative area for all sections for each heart was used for comparisons. All results are expressed as mean±standard error of the mean (SEM). Oneway ANOVA followed by Tukey's post test was used to compare differences in relative infarct size. P<0.05 was considered to be statistically significant.
Tat-Sab Infarct Size Analysis: Direct injections (five 5 µl injections, 2 mg/kg) were delivered 5 minutes before reperfusion into the left ventricle wall in areas below the occlusion site of the LAD (4 injections) and in the apex of the heart (1 injection). Injections were made with a 30 gauge needle (45° bevel) and 10 µl Hamilton syringe. Control groups subjected to the same ischemia/reperfusion (I/R) procedure included a saline injection (I/R+saline), Tat-Scramble peptide injection (I/R+Tat-Scramble), and a Sham group without LAD occlusion. Following 24 hours of reperfusion, the rats were euthanized and hearts were transcardially perfused with cold PBS. The hearts were removed and five to six biventricular sections of similar thickness were made perpendicular to the long axis of the heart and incubated in 1% triphenyl tetrazolium chloride (TTC) in PBS for 10 minutes at 37°C. Samples were stored in 10% formalin. To measure the protective effects of Tat-Sab peptide, each heart section stained with TTC was photographed on both sides for each group (sham, I/R+saline, I/R+Tat-scramble, and I/R+Tat-Sab; n= 4, 8, 7, 8, respectively). The total area of the left ventricle, total area of the apex and infarct size was delineated and calculated for both sides using Adobe Photoshop CS3 software. Infarct area was calculated as the risk area that became necrotic as distinguished by TTC staining. Infarct size was expressed as the ratio of infarct area in both the total area of the left ventricle and total area of the apex. All results are expressed as mean±standard error of the mean (SEM). One-way ANOVA followed by Tukey's post test was used to compare differences in relative infarct size. P<0.05 was considered to be statistically significant.
CPK and CK-MB and TUNEL Staining
Analysis: Blood samples were collected via the lateral tail vein in EDTA tubes for Creatine phosphokinase (CPK) and Creatine Kinase (CK-MB) analysis at 2 hours post reperfusion from rats receiving 5 mg/kg SR-3306 (n=4) and vehicle (DMSO/Tween/H20; n= 3). Blood samples were also collected from naïve rats (n= 4) that did not undergo any procedure. Quantification of apoptosis was measured using the Roche In Situ Cell Death Detection Kit, Fluorescein (Cat. No. 11684795910). Assay procedures were followed for paraffinembedded tissues sections. Following TUNEL and Dapi staining, 30 random sections within the apex and mid section of the left ventricle were imaged for each group (SR-3306, Vehicle, Sham; n= 8, 8, 5 respectively). The apoptotic index, defined as the number of TUNEL positive nuclei (green) divided by the total number of nuclei (blue), was determined by averaging counts from 30 random images from each heart.
4-HNE, Protein Carbonyls, Aconitase:
Left ventricles were lysed on dry ice in M-PER (Thermo-Fisher) supplemented with protease and phosphatase inhibitors. Left ventricle fragments were crushed to powder using a cold mortar and pestle, and the powder was placed in M-PER, and vortexed vigorously. Samples were stored on dry ice for 15 minutes. Samples were centrifuged at 14,000xg for 15 minutes at 4 o C to remove tissue debris. The protein in the homogenate was quantitated using the Peirce BCA Assay Kit protocol. 4-HNE was measured using the Cell BioLabs, Inc. 4-HNE ELISA kit. The Protein Carbonyls Detection Kit and Aconitase Assay Kit were purchased from Cayman Chemicals. Left ventricle lysates were monitored for these oxidative stress markers according to the manufacturers' protocols.
Results
Hydrogen Peroxide-Induced Oxidative Stress Activates JNK Signaling in H9c2 cells
To demonstrate that the JNK pathway was activated under H 2 
Oxidative Stress Causes JNK and MKK4 to
Localize to the Mitochondria Mitochondria were isolated from H9c2 cells treated for 20 minutes with 100 µM H 2 O 2 / FeSO 4 and Western analysis was used to determine if JNK, MKK4, and Sab were localized to the mitochondria. Figure 2 shows that when H9c2 cells were treated with PBS (control) there was no JNK localized to the mitochondria but when treated with 100 µM H 2 O 2 /FeSO 4 the 55kDa splice variant of JNK was found on the mitochondria (Panel A).
Similarly, a 42 kDa band corresponding to MKK4 (an upstream activator of JNK) was only detected in cells treated with 100 µM H 2 O 2 / FeSO 4 suggesting that MKK4, like JNK, was brought to the mitochondria in H9c2 cells under oxidative stress conditions (Figure 2 Panel B).
The putative JNK mitochondrial scaffold protein Sab was also present on the mitochondria (Figure 2 Panel C), and COX-IV (Panel D) and SOD1 (Panel E) were present in equal amounts in both samples suggesting equal loading and confirming JNK and MKK4 localization to the mitochondria. Finally, GAPDH, calnexin, and histone H3 immuno-reactivity are shown to indicate no contribution from other subcellular fractions (Panels F-H). These data suggest that oxidative stress drives JNK and MKK4 to the mitochondria and this may have a significant role in cardiomyocyte function, survival, and death.
To establish that JNK interacts with Sab and MKK4 on the mitochondria under oxidative stress, we treated H9c2 cells with H 2 O 2 /FeSO 4 and immuno-precipitated the mitochondrial complex with Sab and blotted for Sab, JNK, and MKK4. Figure 2I presents Western analysis showing that Sab was located on the mitochondrial membrane (lane 1) when no oxidative stress was applied as expected, whereas JNK and MKK4 were not (lane 1). However, upon treatment of the cells with H 2 O 2 /FeSO 4 , JNK and MKK4 were driven to the mitochondria and were associated with Sab (lane 2, Figure 2I ).
These results suggest that oxidative stress caused JNK and MKK4 to be localized to the mitochondria and that this interaction may be mediated by Sab. Figure 2J presents Western blot analysis of phospho-JNK and JNK in mitochondrial preps from H9c2 cells. The data show JNK and p-JNK were translocated to the mitochondria upon stimulation of H9c2 cells with 100 µM H 2 O 2 /FeSO 4 for 20 min (lane 2) and this translocation was completely blocked by pre-incubation of the cells with 3 µM Tat-Sab peptide (Lane 3). The negative control Tat-Sab scramble peptide had no effect on JNK translocation. The cytosolic/nuclear preps in Figure 2K showed increased p-JNK and p-c-jun after H 2 O 2 / FeSO 4 treatment but no inhibition of c-jun phosphorylation suggesting that Tat-Sab prevented JNK translocation to the mitochondria but does not inhibit JNK activity. Finally, to firmly establish JNK translocation to the outer mitochondrial membrane Figure 3 shows the immunofluorescence from various treatment regimens. Notably, Sab (green) was found on the outer mitochondrial membrane in all groups and p-JNK (red) was absent from the outer mitochondrial membrane in the PBS-treated sample (Figure 3b ) and moved to the outer mitochondrial membrane after H 2 O 2 /FeSO 4 treatment (Figure 3f ) and was blocked from this translocation when Tat-Sab KIM1 was present (Figure 3n) .
JNK Translocation to the Mitochondria is Inhibited by the Tat-Sab Peptide During Oxidative Stress in H9c2 Cells
These results confirm mitochondrial JNK translocation. SR-3306 is a potent, highly selective JNK inhibitor which demonstrates good pharmacokinetic properties in rats (19) . Figure 4A presents treatment. The Tat-scramble peptide had no effect on reducing ROS. A similar effect was seen when MMP was measured by JC-1 detection ( Figure 4B) . Finally, the effect of SR-3306 or Tat-Sab on cell viability in response to oxidative stress was measured by an MTT assay ( Figure 4C) (Figures 4D-F) .
JNK Inhibition and Inhibition of JNK
Activation of the JNK Pathway in vivo During
I/R To demonstrate that the JNK pathway was indeed activated during ischemia/reperfusion, we measured the phospho-c-jun and p-JNK Western blot signal after 30 minutes ischemia and at different time points of reperfusion after ischemia. Figure 5 shows
Similarly, p-JNK levels showed a persistent increase beginning at 30 min and extending to 6 hrs. Tubulin is shown as a loading control. These results indicated that the JNK pathway was activated after I/R and the pc-jun signal endured during at least the first six hours of the reperfusion component of the injury. Figure 6 presents the in vivo efficacy of SR-3306 in anesthetized rats after 30 minutes ischemia and 24 hours reperfusion. Panel A of Figure 6 shows the total area of left ventricle (LV) was the same for the three treatment groups (DMSO, control; 3-aminobenzamide, positive control; and SR-3306). The results show that the total area of LV for each of the three groups was approximately the same ranging from 749±75 in the DMSO group to 700±46 in the SR-3306 treated group. Panel B of Figure 6 shows the total LV % infarct size. The DMSO vehicle treated group showed 29.5±2.7% infarct after I/R. Treatment with 40 mg/kg, 3-aminobenzamide, a positive control for I/R protection, showed the decrease in LV% infarct was 19.7±1.5%, a statistically significant (p = 0.048) effect. Treatment with 5 mg/kg SR-3306 also showed a statistically significant (p < 0.05) decrease where LV % infarct was 20.6±1.7% (a reduction of 30%, p<0.0001). These results show that a modest dose of SR-3306 was protective in the I/R MI rat model.
In vivo Efficacy of SR-3306 in Rats After I/R
SR-3306 Reduced Apoptosis and CPK and CK-MB Activity in vivo
We were able to extend these findings to include quantitative analysis of apoptosis in vivo, as measured by TUNEL staining. Figure 7A -F presents representative DAPI and TUNEL stained sections from two representative sections of the heart comparing sham treated animals to a vehicle-treated I/R group of animals, and a 5 mg/kg SR-3306-treated I/R group of animals. Total number of nuclei (blue) and TUNEL positive cells (green) are shown for each representative section of the heart. The mid section and apex of the heart showed profound apoptosis (panels C and D) for the I/R vehicle treated hearts whereas the SR-3306-treated I/R group showed essentially no apoptosis in the mid section with minimal apoptosis in the apex (panels E and F). Figure 7G presents the % TUNEL positive nuclei determined by averaging counts from 30 random images from each heart. The % TUNEL positive nuclei was defined as the number of TUNEL positive nuclei divided by the total number of nuclei. The profound protection of SR-3306 was seen in the approximate 4-fold decrease (p< 0.01) in the % TUNEL positive nuclei compared to the vehicle treated group. These results extend the findings from the efficacy measures, and further support the protective effect of JNK inhibition in I/R injury and the benefits of utilizing this compound for in vivo probing of the role of JNK in mitochondrial dysfunction. A third measure showing the efficacy of SR-3306 in the MI model is presented in Figure 7H and 7I. Panel H presents the creatine phosphokinase (CPK) activity given in units/liter for naïve rats, rats exposed to I/R injury for two hours, and rats treated with 5 mg/kg SR-3306. The results showed that naïve rats had CPK levels of 22.7 U/L compared to 136.4 U/L for the vehicle treated group. This 6-fold increase in CPK levels was reduced to 50.1 U/L for the SR-3306 treated group, a 2.7-fold decrease compared to the infarcted group (p < 0.05). These results confirmed the protective effect of SR-3306 in this MI model. A similar trend was seen in the measure of Creatine Kinase-MB (CK-MB) activity where CK-MB levels (U/L) are reduced ~ 2-fold by SR-3306 ( Figure 7I ).
Blocking
JNK Translocation to the Mitochondria Protects Against I/R Injury in vivo
To demonstrate that the mechanism by which I/R injury occurred in vivo was through JNK translocation to the mitochondria, we designed a cell permeable Sab peptide to block JNK interaction with Sab(14). Figure 8 presents the protection afforded to both the whole heart and the apex of the left ventricle by 2 mg/kg Tat-Sab after I/R injury. Figures 8A and 8C show that the total area of the left ventricle (LV) was the same for all groups in both the whole heart and apex. Figure 8B shows the whole heart percent infarct for the left ventricle indicating 25.9± 3.9% infarct after I/R. Tat-scramble peptide did nothing to reduce the infarct volume while treatment with 2 mg/kg Tat-Sab reduced the infarct volume to 16.1 ±3.7% (a reduction of 38%, p < 0.0001). The protective effect of TatSab is even more profound if only the apex is considered. Figure 8D shows that the apex only percent infarct for the left ventricle was 45.1± 6.0% infarct after I/R. Again, Tat-scramble peptide did nothing to reduce the infarct volume while treatment with 2 mg/kg Tat-Sab reduced the infarct volume to 19.9 ±5.9% (a reduction of 56%, p < 0.0001).
In vivo Measures of Oxidative Stress in the Left Ventricle of Rat Hearts After I/R
To correlate the protected infarct volumes afforded by blocking JNK translocation to the mitochondria by Tat-Sab to measures of oxidative stress, we measured 4-hydroxynonenal (4-HNE; a measure of lipid peroxidation), protein carbonyls, and aconitase activity in the presence and absence of Tat-Sab during I/R. 4-HNE levels were increased 8.8-fold (p <0.05) during I/R compared to sham, and were reduced by 2.5-fold (p <0.05) when I/R happened in the presence of 2 mg/kg Tat-Sab ( Figure 9A ). Similarly protein carbonylation was increased 9.4-fold (p <0.05) during I/R compared to sham, but this change was reduced by 2.6-fold (p <0.05) in the presence of 2 mg/kg Tat-Sab ( Figure 9B ).
Finally aconitase activity, a measure of redox activity in the cell, was decreased by 13-fold (p <0.05) during I/R compared to sham, and this was restored to approximately 60% the value of the sham group when I/R happened in the presence of 2 mg/kg Tat-Sab ( Figure 9C ).
Discussion
A body of evidence is growing to indicate that JNK-induced apoptosis is more dynamic than mere induction of AP-1-mediated transcription. Indeed, Aoki et al. established that oxidative stress-induced apoptosis in cardiomyocytes did not require new protein synthesis and was more dependent on mitochondrial mechanisms(1). Our work, in HeLa cells, also showed that 80% of ROS generated after an initial oxidative stress was JNK-dependent and this affected mitochondrial physiology and cell death (6) . Hawana et al. also observed a mitochondrialderived increase in ROS that was JNK dependent in acetaminophen-induced liver injury where JNK was translocated to the mitochondria and mitochondrial dysfunction was observed (2) . Given these findings, we set out to establish that blocking JNK translocation to the mitochondria could have similar therapeutic benefit in cardiovascular I/R models as inhibition of JNK activity. To do this we developed a biochemical probe (Tat-Sab KIM1 ) to interrogate mitochondrial function independently from transcriptional regulation.
The results here support the following conclusions.
First, the JNK pathway was activated in response to oxidative stress in rat cardiomyocyte-like H9c2 cells under the same time course as it was in rats exposed to 30 minutes ischemia and varying time points of reperfusion injury (compare Figures 1 and 5) suggesting that the H9c2 cell system is a reasonable model for in vivo I/R injury. Interestingly, the time course for JNK activation in H9c2 cells and in vivo in our study showed a maximal activation of JNK around six hours which was identical to the time course seen for JNK activation in whole cell fractions isolated from rat brains subjected to middle cerebral artery occlusion (MCAO) (21) . The same was true for acetaminophen-induced liver injury where JNK activation peaked at six hours as measured by p-JNK Western and this correlated with peak serum alanine transaminase (ALT) levels. These results suggest that JNK activation induced either by I/R injury or acetaminophen could be a universal response in various organs and that the time course for activation and cell deaths may be similar among these tissues.
Secondly, we can conclude from our data that JNK translocation to the mitochondria occurred rapidly in rat H9c2 cells and that the proportion of active JNK (i.e. p-JNK) increased over time peaking near six hours (Figures 1 and 2) . Again, our results correlate nicely with those found by Aoki et al. who showed by immunofluorescence and confocal microscopy that endogenous MKK4 and JNK1 both translocated to the mitochondria very rapidly in adult rat primary cardiomyocytes exposed to oxidative stress (1) . This time course is also consistent with what we found for anisomycin-induced stress in HeLa cells (6, 14) . Thirdly, concurrent with the JNK activation, mitochondrial ROS generation and mitochondrial membrane dissipation occurred, leading to cell death (Figure 4) . It is here where our studies extend beyond what was found by Aoki et al as they did not have any measures for ROS generation, or mitochondrial function. Thus our study is the first report for these mitochondrial function measures in rat and human cardiomyocytes. Moreover, the near equal protection for mitochondrial function ( Figure 4B and 4E) against oxidative stress by either 500 nM SR-3306, 500 nM SR-3562, or 10 µM Tat-Sab in these cells suggests that inhibition of JNK mitochondrial signaling may be similarly as effective as inhibition of JNK activity in protecting the cell against mitochondrial dysfunction and cell death initiated by oxidative stress.
It is important to note that while most studies in most cells and most tissues support our findings, there are a few reports from the Webster group (22, 23) which show that JNK activation is protective against oxidative stress and reperfusion in primary neonatal rat cardiomyocytes. In those studies the Webster group either transfected primary neonatal rat cardiomyocytes with dominant negative (dn) JNK1 or infected these cells with adenoviral expressed dnJNK1. In each case, they saw an increase in apoptosis associated with dnJNK1 expression suggesting a protective effect for JNK1. This is opposite to what we see and that seen by Gottlieb and colleagues(12) who saw protective effects from dnJNK2 that was adenovirally expressed in primary adult rabbit cardiomyocytes. The Gottlieb lab also saw protective effects from adenoviral expression of JIP (a JNK inhibitor) suggesting that JNK inhibition, not activation was protective in oxidative stress and I/R-stress models both in vitro and in vivo. Moreover, Gottleib and colleagues found that TNFα-activated JNK activity in H9c2 cells was completed abolished by dnJNK2 and JIP-1(12), a result very much in line with our findings and again suggesting that JNK inhibition, not activation is protective. One potential reason for the discrepancy between our findings and those from Webster may be that like Aoki et al. and the Gottlieb group we utilized adult cardiomyocytes or tissues from adult animals whereas the Webster findings all come from neonatal rat cardiomyocytes. This notion is supported by the fact that JNK1 is not expressed in human fetal heart(24), making the overexpression of dnJNK1 in the neonatal cells perhaps non-physiologic. Along the same lines, a second potential reason for the discrepancy between our findings and those from Webster may be that our system utilized the endogenous expression levels of all JNKs in the cell whereas the Webster work relied upon overexpression of dominant negative forms of JNK1 which may have altered the balance of JNK isoform function within the cell that were not at physiological levels. A third reason may be that JNK isoform contributions to protection and cell death may vary. For example, Yu et al. showed that jnk3 -/-mice had significantly reduced infarct volumes in the brain after 30 minutes ischemia and 24 hr reperfusion in the MCAO model (25) . JNK3 is solely expressed in the heart and brain and may have unique roles in those tissues(26).
Similarly Gottlieb and colleagues showed protective effects in the dnJNK2 studies cited above again suggesting that different JNK isoforms may have tissue specific protective roles. In our studies we utilized physiologic levels of all three isoforms which may best reflect native contributory responses to oxidative stress and I/R stress in vitro and in vivo.
It has already been established that inhibition of JNK by small molecule inhibitors reduced infarct size in rats after myocardial ischemia (11) . Our goal was to compare the efficacy of SR-3306 in reducing infarct volume to that of Tat-Sab and correlating other biomarkers such as CPK and CK-MB and apoptotic index for SR-3306 with protection of oxidative stress in vivo by Tat-Sab as well as to compare SR-3306 to AS601245. First, it should be noted that SR-3306 compared very favorably to AS601245 in that the reduction in infarct size with 5 mg/kg SR-3306 was equivalent to that of both 4.5 mg/kg and 15 mg/kg AS601245. Since higher doses of SR-3306 were not tried, it is not known if higher doses would produce a further lowering of infarct size than that obtained with higher doses (15 mg/kg) of AS601245. Similarly both AS601245 and SR-3306 reduced the number of TUNEL positive cells by approximately 4-fold again suggesting equal efficacy for both compounds. The reductions in apoptosis and infarct size for SR-3306 also correlated with drops in CPK and CK-MB suggesting that reduction in infarct volume and apoptosis correlated well with these blood biomarkers of myocardial infarction (MI) suggesting SR-3306 was indeed protective against the I/R injury.
In comparing the efficacy from small molecule JNK inhibitors such as SR-3306 and AS601245 to that of Tat-Sab it was immediately evident that inhibiting JNK mitochondrial translocation provided similar benefit for reducing infarct volume as did universal JNK inhibition ( Figures  6 and 8) . A few caveats must be stated however. First, Tat-Sab was delivered directly into the rat myocardium whereas SR-3306 was delivered by constant infusion. If the local dose of Tat-Sab was significantly higher than that of SR-3306 a direct comparison cannot be made. Conversely, rapid loss of Tat-Sab in vivo could theoretically produce lower concentrations than SR-3306. Despite this, it can be stated that similar protection was afforded by the two mechanisms of inhibition and careful dose-response analysis would allow for quantitative comparison of efficacy for the two inhibition mechanisms. This result suggests that inhibition of JNK translocation to the mitochondria (and therefore JNK mitochondrial signaling) could possibly be at least partially responsible for JNKs protective effects against I/R. This observation may have a profound effect on how therapeutic strategies may be considered and pursued. For example, if therapeutic benefit could be achieved by selectively inhibiting JNK mitochondrial signaling without affecting nuclear function as we have previously demonstrated(14), it can be conceived that any potential toxicities associated with inhibiting nuclear JNK signaling would be eliminated while still maintaining maximal therapeutic benefit. Given that the JNK-Sab interaction has significant affinity contributions from the 11-amino acid KIM domain as evidenced by the 218 nM IC 50 for Tat-Sab KIM1 versus Sab protein(14), the notion of making Sab competitive small molecule inhibitors or bidentate small molecule JNK inhibitors that span the ATP pocket as well as the substrate binding domain is feasible. Indeed, a few such compounds have been reported on that are either competitive versus JIP (27) , or having some bidentate character (28) (29) (30) (31) . If these compounds can be improved upon for potency, selectivity, and drug like properties, our results now show that selective inhibition of JNK mitochondrial signaling might be achieved with therapeutic benefit. Finally, the changes in 4-HNE, protein carbonyls and aconitase activity levels in the presence of Tat-Sab further illustrates that selective inhibition of mitochondrial JNK signaling impacts oxidative stress in vivo suggesting key mechanistic roles for JNK in these processes.
In summary, this is the first demonstration on the molecular level which shows that blocking JNK mitochondrial signaling via inhibition of JNK interaction with Sab can be protective against in vivo I/R. Moreover, it is important to stress that the effect seen with inhibiting JNK mitochondrial signaling was similarly efficacious as universal JNK inhibition. In addition these results provide a mechanism by which JNK-driven mitochondrial generated ROS causes mitochondrial dysfunction in cardiomyocytes and that blocking the molecular interaction between JNK and Sab mitigates these dysfunctions manifesting in significantly reduced infarct volumes, apoptosis, and oxidative stress in vitro and in vivo. These studies lay the foundation for designing mitochondrial specific JNK signaling inhibitors that may reduce any toxicities seen with JNKdependent nuclear inhibition. Phosphorylation of c-Jun and JNK was evaluated by Western blot following 30 minutes, 1, 2, and 6 hours of reperfusion after 30 minutes ischemia. Rat hearts were transcardially perfused with cold PBS (pH 7.4) and myocardial tissue of the left ventricle was collected and frozen in liquid N 2 prior to analysis. 30µg of total protein were loaded on the gel and resolved by SDS-PAGE. Total c-jun levels and α-Tubulin were used as loading controls. The selective JNK inhibitor SR-3306 decreases apoptosis and CPK and CK-MB levels in rat hearts during I/R injury in vivo. SR-3306 was given first as a bolus dose five minutes prior to onset of reperfusion and then administered by constant infusion at a rate of 18 µg/kg/min during the reperfusion phase to yield a final total dose of 5 mg/kg. A-F) DAPI and TUNEL stained sections from two representative sections of the heart comparing sham treated animals to a vehicle-treated I/R group of animals, and a 5 mg/kg SR-3306-treated I/R group of animals. Total number of nuclei (blue) and TUNEL positive cells (green) are shown for each representative section of the heart. G) % TUNEL positive nuclei determined by averaging counts from 30 random images from each heart. The % TUNEL positive nuclei was defined as the number of TUNEL positive nuclei divided by the total number of nuclei. H) Creatine phosphokinase (CPK) activity given in units/liter for naïve rats, rats exposed to I/R injury for two hours, and rats treated with 5 mg/kg SR-3306. I) Creatine kinase-MB (CK-MB) activity given in units/liter for naïve rats, rats exposed to I/R injury for two hours, and rats treated with 5 mg/kg SR-3306. The in vivo efficacy of Tat-Sab KIM1 in anesthetized rats after 30 minutes ischemia and 24 hours reperfusion. Tat-Sab KIM1 was given five minutes before reperfusion as a total of five direct injections into the left ventricle wall in areas below the occlusion site of the LAD (4 injections) and in the apex of the heart (1 injection). The total final dose of Tat-Sab KIM1 was 2 mg/kg. A) The total area of the left ventricle (LV) was measured by triphenyl tetrazolium chloride (TTC) staining for four treatment groups: Sham; I/R + saline; I/R + 2 mg/kg Tat-scramble; and I/R + 2 mg/kg TatSab KIM1 . B) Total LV % infarct for the four treatment groups described in A. C) The total area of the apex) was measured by TTC staining for four treatment groups described in A. D) Total apex % infarct for the four treatment groups described in A.
Figure 9:
In vivo measures of oxidative stress in the left ventricle of rat hearts after 30 minutes ischemia and 24 hours reperfusion. Tat-Sab KIM1 was given five minutes before reperfusion as a total of five direct injections into the left ventricle wall in areas below the occlusion site of the LAD (4 injections) and in the apex of the heart (1 injection). The total final dose of TatSab KIM1 was 2 mg/kg. A) 4-hydroxynonenal (4-HNE) levels for four treatment groups: Naïve, Sham; I/R; and I/R + 2 mg/kg Tat-Sab KIM1 . B) Protein Carbonyl levels for four treatment groups: Naïve, Sham; I/R; and I/R + 2 mg/kg Tat-Sab KIM1 . C) Aconitase Activity for four treatment groups: Naïve, Sham; I/R; and I/R + 2 mg/kg Tat-Sab KIM1 . 
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